Efficacy of auricular stimulation in the treatment of diarrhoeal irritable bowel syndrome and the mechanism of brain network modulation

注册号:

Registration number:

ITMCTR2024000232

最近更新日期:

Date of Last Refreshed on:

2024-08-13

注册时间:

Date of Registration:

2024-08-13

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

耳穴刺激治疗腹泻型肠易激综合征疗效观察及脑网络调制机制

Public title:

Efficacy of auricular stimulation in the treatment of diarrhoeal irritable bowel syndrome and the mechanism of brain network modulation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

耳穴刺激治疗腹泻型肠易激综合征疗效观察及脑网络调制机制

Scientific title:

Efficacy of auricular stimulation in the treatment of diarrhoeal irritable bowel syndrome and the mechanism of brain network modulation

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李少源

研究负责人:

李少源

Applicant:

Shaoyuan Li

Study leader:

Shaoyuan Li

申请注册联系人电话:

Applicant telephone:

+86 159 0149 8725

研究负责人电话:

Study leader's telephone:

+86 159 0149 8725

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

704488328@qq.com

研究负责人电子邮件:

Study leader's E-mail:

704488328@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市东城区东直门内南小街16号

研究负责人通讯地址:

北京市东城区东直门内南小街16号

Applicant address:

16 Nanxiao street, Dongzhimen, Dongcheng District, Beijing

Study leader's address:

16 Nanxiao street, Dongzhimen, Dongcheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院针灸研究所

Applicant's institution:

Institute of acupuncture and moxibustion, China Academy of Chinese Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

中科针伦(S2024-01-26-5)

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

中国中医科学院针灸研究所伦理委员会

Name of the ethic committee:

Ethics Committee of Institute of acupuncture and moxibustion, China Academy of Chinese Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2024/2/21 0:00:00

伦理委员会联系人:

徐东升 张艳宏

Contact Name of the ethic committee:

Dongsheng Xu, Yanhong Zhang

伦理委员会联系地址:

北京市东城区东直门内南小街16号

Contact Address of the ethic committee:

16 Nanxiao street, Dongzhimen, Dongcheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 6408 9307

伦理委员会联系人邮箱:

Contact email of the ethic committee:

gamhec@126.com

研究实施负责(组长)单位:

中国中医科学院针灸研究所

Primary sponsor:

Institute of acupuncture and moxibustion, China Academy of Chinese Medical Sciences

研究实施负责(组长)单位地址:

北京市东城区东直门内南小街16号

Primary sponsor's address:

16 Nanxiao street, Dongzhimen, Dongcheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院针灸研究所

具体地址:

北京市东城区东直门内南小街16号

Institution
hospital:

Institute of acupuncture and moxibustion, China Academy of Chinese Medical Sciences

Address:

16 Nanxiao street, Dongzhimen, Dongcheng District, Beijing

经费或物资来源:

中国中医科学院针灸研究所

Source(s) of funding:

Institute of acupuncture and moxibustion, China Academy of Chinese Medical Sciences

研究疾病:

腹泻型肠易激综合征

研究疾病代码:

Target disease:

Diarrhoeal Irritable Bowel Syndrome

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

对耳穴刺激治疗腹泻型肠易激综合征进行疗效观察及脑网络调制机制研究。

Objectives of Study:

To observe the efficacy of auricular acupoint stimulation in the treatment of diarrhoeal irritable bowel syndrome and to investigate its mechanism of brain network modulation.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1. 年龄18~65岁,男女不限; 2. 符合腹泻型肠易激综合征诊断; 3. 患者自愿签署知情同意书。

Inclusion criteria

1. Patients aged between 18 and 65 years of age, male or female; 2. Meeting the diagnosis of diarrhoeal irritable bowel syndrome; 3. Patients voluntarily sign an informed consent form.

排除标准:

1)既往有溃疡、肿瘤等消化道器质性病变患者; 2)患有甲状腺、糖尿病等影响胃肠道动力的疾病; 3)严重的心、肝、肾、肺、血液等系统性疾病; 4)有精神、心理疾病及相关病史的患者; 5)有胃肠手术重大病史的患者; 6)计划怀孕、孕妇及哺乳期的患者; 7)耳甲区皮损严重、耳郭缺如的患者。

Exclusion criteria:

1) Patients with previous organic lesions of the gastrointestinal tract such as ulcers and tumours; 2) Diseases affecting gastrointestinal tract dynamics such as thyroid and diabetes mellitus; 3) Serious systemic diseases such as heart, liver, kidney, lung and blood; 4) Patients with mental and psychological diseases and related medical history; 5) Patients with significant medical history of gastrointestinal surgery; 6) Patients who are planning to be pregnant, pregnant women and breastfeeding; 7) Patients with severe skin lesions in the auricular region and absence of the auricle.

研究实施时间:

Study execute time:

From 2023-12-01

To      2026-11-30

征募观察对象时间:

Recruiting time:

From 2024-08-15

To      2026-09-30

干预措施:

Interventions:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

外耳非迷走神经刺激,取“肩”、“腕”耳穴进行刺激。

干预措施代码:

Intervention:

Transcutaneous non-vagus nerve stimulation, taking the "shoulder" and "wrist" auricular points for stimulation.

Intervention code:

组别:

治疗组

样本量:

30

Group:

Treatment group

Sample size:

干预措施:

经皮耳迷走神经刺激,取“肝”、“脾”耳穴进行刺激。

干预措施代码:

Intervention:

Transcutaneous auricular vagus nerve stimulation, taking "liver" and "spleen" auricular points for stimulation.

Intervention code:

样本总量 Total sample size : 60

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院广安门医院

单位级别:

三甲

Institution/hospital:

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

17项汉密尔顿抑郁量表评分

指标类型:

次要指标

Outcome:

17-HAMD

Type:

Secondary indicator

测量时间点:

基线、第4周末。

测量方法:

Measure time point of outcome:

Baseline, end of week 4.

Measure method:

指标中文名:

布里斯托粪便性状量表

指标类型:

次要指标

Outcome:

Bristol Stool Form Scale

Type:

Secondary indicator

测量时间点:

基线、第4周末。

测量方法:

Measure time point of outcome:

Baseline, end of week 4.

Measure method:

指标中文名:

IBS病情严重程度量表

指标类型:

主要指标

Outcome:

IBS-SSS

Type:

Primary indicator

测量时间点:

基线、第2周、第4周末。

测量方法:

Measure time point of outcome:

Baseline, end of week 2, week 4.

Measure method:

指标中文名:

功能磁共振成像

指标类型:

次要指标

Outcome:

functional magnetic resonance imaging

Type:

Secondary indicator

测量时间点:

基线、第4周末。

测量方法:

Measure time point of outcome:

Baseline, end of week 4.

Measure method:

指标中文名:

心率变异性

指标类型:

次要指标

Outcome:

Heart rate variability(HRV)

Type:

Secondary indicator

测量时间点:

基线、第4周末。

测量方法:

Measure time point of outcome:

Baseline, end of week 4.

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

按照1:1的比例将受试者随机分配到治疗组和对照组。采用SAS 9.4统计分析软件的“Proc plan”程序产生研究所需的随机方案。随机化过程中设定的各参数等相关内容均保存在盲底中。采用临床研究中央随机系统进行随机化操作。当合格受试者入组时,由分中心负责随机化的人员登陆中央随机系统机型随机号的申请。

Randomization Procedure (please state who generates the random number sequence and by what method):

Subjects were randomly assigned to treatment and control groups in a ratio of 1:1. The "Proc plan" procedure of SAS 9.4 statistical analysis software was used to generate the randomization plan required for the study. The parameters set during the randomization process were stored in a blinded database. Randomization was carried out using the Central Randomization System for Clinical Research. When eligible subjects are enrolled, the person in charge of randomization at each center logs on to the central randomization system to request a random number.

盲法:

对受试者施盲。

Blinding:

Blinding the subjects.

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

临床中心核对全部临床试验资料并进行妥善保存和管理。指定专人负责采集、录入所有数据。待试验完成后,临床中心必须将已录入数据文件及临床病例报告表(Case report form, CRF 表)上交。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The Clinical Centre collates all clinical trial data and maintains and manages them appropriately. A designated person is responsible for the collection and entry of all data. Upon completion of the trial, the clinical centre must submit the entered data files and the clinical case report form (CRF form).

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above